Here we aim to discuss the main challenges related to APOL1 testing in CKD in admixed populations and the opportunities to better understand how genomic studies on CKD could transform precision medicine strategies through the inclusion of genetic diversity (Table 1; Figure 1). The gene discussed is APOL1; the disease is chronic kidney disease.